subscribeSubscribe
BioMarin`s Roctavian, once forecast to sell $50M to $150M last year, only pulls in a fraction of that

BioMarin`s Roctavian, once forecast to sell $50M to $150M last year, only pulls in a fraction of that
ENDPTS
23 Feb 2024
Share Share
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability

BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability
PR NEWSWIRE
06 Feb 2024
Share Share
BioMarin First Person Treated Commercially with ROCTAVIAN Se.Hemophilia A in EU

BioMarin First Person Treated Commercially with ROCTAVIAN Se.Hemophilia A in EU
PR NEWSWIRE
30 Aug 2023
Share Share
BioCareSD Builds Depth as Limited Specialty Distributor by Adding ROCTAVIAN™, RYSTIGGO®, VYVGART® HYTRULO to Portfolio

BioCareSD Builds Depth as Limited Specialty Distributor by Adding ROCTAVIAN™, RYSTIGGO®, VYVGART® HYTRULO to Portfolio
PR NEWSWIRE
11 Jul 2023
Share Share
Orsini Selected by BioMarin to Dispense ROCTAVIAN

Orsini Selected by BioMarin to Dispense ROCTAVIAN
PR NEWSWIRE
11 Jul 2023
Share Share
US FDA approves BioMarin`s gene therapy for hemophilia A

US FDA approves BioMarin`s gene therapy for hemophilia A
REUTERS
30 Jun 2023
Share Share
U.S. Food and Drug Administration Approves BioMarin`s ROCTAVIAN™

U.S. Food and Drug Administration Approves BioMarin`s ROCTAVIAN™
PR NEWSWIRE
29 Jun 2023
Share Share
BioMarin wins approval for gene therapy to treat hemophilia A

BioMarin wins approval for gene therapy to treat hemophilia A
Adam Feuerstein STAT NEWS
29 Jun 2023
Share Share
BioMarin to Present ROCTAVIAN Data from Hemophilia Gene Therapy Trial Program

BioMarin to Present ROCTAVIAN Data from Hemophilia Gene Therapy Trial Program
PRESS RELEASE
22 Jun 2023
Share Share
BioMarin gets first access deal in EU for gene therapy Roctavian

BioMarin gets first access deal in EU for gene therapy Roctavian
PHARMAPHORUM
12 Jan 2023
Share Share